Lyell Immunopharma Inc Financial Flexibility Index
Lyell Immunopharma Inc financial flexibility index. Lyell Immunopharma Inc (LYEL) has a Financial Flexibility Index of -0.44x as of June 2026. Free cash flow of $-33.67 Million (operating CF $-33.92 Million minus capex $256.00K) represents 0% of total liabilities ($77.34 Million). See Lyell Immunopharma Inc (LYEL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Lyell Immunopharma Inc (2019–2025)
Financial flexibility index of Lyell Immunopharma Inc from 2019 to 2025. Historical Financial Flexibility Index trend for Lyell Immunopharma Inc across 7 annual periods. Explore Lyell Immunopharma Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Lyell Immunopharma Inc Financial Flexibility Index by Year (2019–2025)
Lyell Immunopharma Inc financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for Lyell Immunopharma Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Lyell Immunopharma Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.62x | $-149.24 Million | $-150.02 Million | $91.85 Million | ▼ -8.4% |
| 2024 | -1.50x | $-161.93 Million | $-162.39 Million | $108.03 Million | ▲ +11.5% |
| 2023 | -1.69x | $-161.01 Million | $-163.69 Million | $95.08 Million | ▼ -21.6% |
| 2022 | -1.39x | $-145.28 Million | $-169.56 Million | $104.31 Million | ▼ -353.1% |
| 2021 | -0.31x | $-60.74 Million | $-126.25 Million | $197.62 Million | ▲ +46.7% |
| 2020 | -0.58x | $-109.39 Million | $-160.87 Million | $189.84 Million | ▼ -253.2% |
| 2019 | 0.38x | $55.52 Million | $39.47 Million | $147.58 Million | — |